ValuEngine cut shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a sell rating in a report released on Tuesday, ValuEngine reports.

Other analysts also recently issued reports about the company. Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a research report on Wednesday, May 15th. BidaskClub cut shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, June 26th. Finally, TheStreet cut shares of TRI Pointe Group from a b- rating to a c+ rating in a report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $18.00.

OXFD opened at $12.71 on Tuesday. The firm has a market capitalization of $336.52 million, a PE ratio of 24.92 and a beta of 0.35. Oxford Immunotec Global has a 1 year low of $11.66 and a 1 year high of $19.19. The company has a current ratio of 12.60, a quick ratio of 12.03 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $13.74.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.14. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The firm had revenue of $14.79 million during the quarter, compared to the consensus estimate of $13.74 million. During the same period last year, the business posted ($0.40) earnings per share. The business’s revenue for the quarter was up 26.6% compared to the same quarter last year. As a group, research analysts forecast that Oxford Immunotec Global will post -0.24 earnings per share for the current year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total value of $48,150.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $48,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.21% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. FIL Ltd bought a new position in Oxford Immunotec Global during the first quarter valued at $5,586,000. EAM Global Investors LLC purchased a new position in Oxford Immunotec Global during the 1st quarter valued at about $1,330,000. Marshall Wace LLP purchased a new position in Oxford Immunotec Global during the 1st quarter valued at about $1,185,000. Granite Investment Partners LLC purchased a new position in Oxford Immunotec Global during the 1st quarter valued at about $1,174,000. Finally, Millennium Management LLC lifted its position in Oxford Immunotec Global by 117.2% during the 4th quarter. Millennium Management LLC now owns 117,914 shares of the company’s stock valued at $1,507,000 after acquiring an additional 63,617 shares during the period. 91.19% of the stock is currently owned by institutional investors.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Read More: Why does a company issue an IPO?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.